Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/96264
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJuliachs Milà, Mercè-
dc.contributor.authorVidal-Bel, August-
dc.contributor.authorGarcía del Muro Solans, Xavier-
dc.contributor.authorPiulats, Josep M.-
dc.contributor.authorCondom i Mundó, Enric-
dc.contributor.authorCasanovas i Casanovas, Oriol-
dc.contributor.authorGraupera i Garcia-Milà, Mariona-
dc.contributor.authorGermà Lluch, José Ramón-
dc.contributor.authorVillanueva Garatachea, Alberto-
dc.contributor.authorViñals Canals, Francesc-
dc.date.accessioned2016-03-08T17:54:31Z-
dc.date.available2016-03-08T17:54:31Z-
dc.date.issued2013-08-10-
dc.identifier.issn1471-2407-
dc.identifier.urihttp://hdl.handle.net/2445/96264-
dc.description.abstractBackground: Cisplatin (CDDP) resistance in testicular germ cell tumors (GCTs) is still a clinical challenge, and one associated with poor prognosis. The purpose of this work was to test pazopanib, an anti-tumoral and anti-angiogenic multikinase inhibitor, and its combination with lapatinib (an anti-ErbB inhibitor) in mouse orthotopic models of human testicular GCTs. Methods: We used two different models of human testicular GCTs orthotopically grown in nude mice; a CDDP-sensitive choriocarcinoma (TGT38) and a new orthotopic model generated from a metastatic GCT refractory to first-line CDDP chemotherapy (TGT44). Nude mice implanted with these orthotopic tumors were treated with the inhibitors and the effect on tumoral growth and angiogenesis was evaluated. Results: TGT44 refractory tumor had an immunohistochemical profile similar to the original metastasis, with characteristics of yolk sac tumor. TGT44 did not respond when treated with cisplatin. In contrast, pazopanib had an anti-angiogenic effect and anti-tumor efficacy in this model. Pazopanib in combination with lapatinib in TGT38, an orthotopic model of choriocarcinoma had an additive effect blocking tumor growth. Conclusions: We present pazopanib as a possible agent for the alternative treatment of CDDP-sensitive and CDDP-refractory GCT patients, alone or in combination with anti-ErbB therapies.-
dc.format.extent10 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBioMed Central-
dc.relation.isformatofReproducció del document publicat a: http://dx.doi.org/10.1186/1471-2407-13-382-
dc.relation.ispartofBMC Cancer, 2013, vol. 13, num. 382-
dc.relation.urihttp://dx.doi.org/10.1186/1471-2407-13-382-
dc.rightscc-by (c) Juliachs Milà, Mercè et al., 2013-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.subject.classificationCàncer-
dc.subject.classificationMalalties del testicle-
dc.subject.classificationTumors-
dc.subject.classificationCisplatí-
dc.subject.otherCancer-
dc.subject.otherTestis diseases-
dc.subject.otherTumors-
dc.subject.otherCisplatin-
dc.titleEffectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec638374-
dc.date.updated2016-03-08T17:54:36Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
638374.pdf1.05 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons